NO962526D0 - Fremgangsmåte for forebyggelse eller behandling av en sykdom karakterisert ved neoplasmatiske celler som uttrykker CD 40 - Google Patents

Fremgangsmåte for forebyggelse eller behandling av en sykdom karakterisert ved neoplasmatiske celler som uttrykker CD 40

Info

Publication number
NO962526D0
NO962526D0 NO962526A NO962526A NO962526D0 NO 962526 D0 NO962526 D0 NO 962526D0 NO 962526 A NO962526 A NO 962526A NO 962526 A NO962526 A NO 962526A NO 962526 D0 NO962526 D0 NO 962526D0
Authority
NO
Norway
Prior art keywords
disease characterized
treating
preventing
cells expressing
express
Prior art date
Application number
NO962526A
Other languages
English (en)
Other versions
NO320354B1 (no
NO962526L (no
Inventor
Richard J Armitage
William C Fanslow
Dan L Longo
William J Murphy
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22628670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO962526(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO962526D0 publication Critical patent/NO962526D0/no
Publication of NO962526L publication Critical patent/NO962526L/no
Publication of NO320354B1 publication Critical patent/NO320354B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19962526A 1993-12-23 1996-06-14 Anvendelse av et CD40-bindende protein som har evne til a binde CD40 og hindrer binding av CD40 til CD40-L ved fremstilling av et middel for forebyggelse eller behandling av en neoplasmatisk sykdom. NO320354B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17266493A 1993-12-23 1993-12-23
PCT/US1994/014767 WO1995017202A1 (en) 1993-12-23 1994-12-21 Method of preventing or treating disease characterized by neoplastic cells expressing cd40

Publications (3)

Publication Number Publication Date
NO962526D0 true NO962526D0 (no) 1996-06-14
NO962526L NO962526L (no) 1996-08-23
NO320354B1 NO320354B1 (no) 2005-11-28

Family

ID=22628670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19962526A NO320354B1 (no) 1993-12-23 1996-06-14 Anvendelse av et CD40-bindende protein som har evne til a binde CD40 og hindrer binding av CD40 til CD40-L ved fremstilling av et middel for forebyggelse eller behandling av en neoplasmatisk sykdom.

Country Status (13)

Country Link
US (1) US5674492A (no)
EP (1) EP0751781B1 (no)
JP (1) JPH09507074A (no)
AT (1) ATE267607T1 (no)
AU (1) AU680102B2 (no)
CA (1) CA2179196A1 (no)
DE (1) DE69433820T2 (no)
DK (1) DK0751781T3 (no)
ES (1) ES2222463T3 (no)
NO (1) NO320354B1 (no)
NZ (1) NZ278740A (no)
PT (1) PT751781E (no)
WO (1) WO1995017202A1 (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997022256A1 (en) * 1995-12-19 1997-06-26 National Jewish Center For Immunology And Respiratory Medicine Method to regulate cd40 signaling
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
JP2001508450A (ja) * 1997-01-10 2001-06-26 バイオジェン インコーポレイテッド 抗ｃｄ４０ｌ化合物の治療学的投与の方法
EP1019034A2 (en) * 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
JP2001526241A (ja) * 1997-12-19 2001-12-18 イミュネックス・コーポレーション Ｈｉｖ感染に対する感受性を低下させるための方法
US7338767B1 (en) * 1998-01-14 2008-03-04 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis, prognosis and/or treatment of melanoma
AU2114999A (en) * 1998-01-14 1999-08-02 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis of melanoma
US5965712A (en) * 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
US6284742B1 (en) * 1998-09-29 2001-09-04 Uab Research Foundation Immunomodulation by genetic modification of dendritic cells and B cells
JP2002533118A (ja) * 1998-12-29 2002-10-08 ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ Ｔ細胞レセプター使用を改変するためのｃｄ４０係合の使用
AU5178800A (en) * 1999-06-01 2000-12-18 Cornell Research Foundation Inc. Activation of dendritic cells to enhance immunity
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001236621B2 (en) 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
WO2001077342A1 (en) 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001259142C1 (en) * 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
ATE313334T1 (de) * 2000-04-25 2006-01-15 Immunex Corp Behandlung von tumoren mit photodynamischer therapie
ATE541860T1 (de) 2000-10-02 2012-02-15 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40 zur therapie von b- zell tumoren
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
EP1372724A2 (en) 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
EP2243492A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
SI1680141T1 (sl) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
DE602004028037D1 (de) 2003-11-04 2010-08-19 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs mit expression des cd40-antigens
EP1682177B8 (en) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
ATE516819T1 (de) 2003-11-04 2011-08-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von b-zell-bedingtem krebs
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
US8333970B2 (en) 2005-05-18 2012-12-18 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
EP1945260B1 (en) 2005-11-01 2012-10-24 Novartis AG Uses of anti-cd40 antibodies
AU2007240507B2 (en) 2006-04-21 2013-07-18 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
CN101479375B (zh) 2006-05-03 2016-03-30 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
WO2009062125A1 (en) 2007-11-07 2009-05-14 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
CN102459639A (zh) 2009-04-18 2012-05-16 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
MX354243B (es) 2011-04-21 2018-02-20 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40.
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
WO2014070934A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
JP6820565B2 (ja) * 2016-04-27 2021-01-27 国立大学法人大阪大学 病原性細菌の定着を阻害するペプチド及びそれを含む定着阻害剤
MX2018016364A (es) 2016-06-20 2019-11-28 Kymab Ltd Anticuerpos anti-pd-l1.
CN116963774A (zh) 2021-01-28 2023-10-27 瑞泽恩制药公司 用于治疗细胞因子释放综合征的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2121798C (en) * 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment

Also Published As

Publication number Publication date
PT751781E (pt) 2004-09-30
EP0751781A1 (en) 1997-01-08
ATE267607T1 (de) 2004-06-15
DE69433820T2 (de) 2005-06-23
US5674492A (en) 1997-10-07
WO1995017202A1 (en) 1995-06-29
ES2222463T3 (es) 2005-02-01
DE69433820D1 (de) 2004-07-01
EP0751781A4 (en) 1999-09-22
AU1516895A (en) 1995-07-10
EP0751781B1 (en) 2004-05-26
JPH09507074A (ja) 1997-07-15
CA2179196A1 (en) 1995-06-29
NO320354B1 (no) 2005-11-28
NZ278740A (en) 1998-05-27
DK0751781T3 (da) 2004-08-09
NO962526L (no) 1996-08-23
AU680102B2 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
NO962526L (no) Fremgangsmåte for forebyggelse eller behandling av en sykdom karakterisert ved neoplasmatiske celler som uttrykker CD 40
Paronetto et al. Chronic liver injury induced by immunologic reactions. Cirrhosis following immunization with heterologous sera.
Fleischmajer The pathophysiology of scleroderma.
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
BR9306226A (pt) Composiçao de cura de feridas e tratamento de distúrbios fibróticos e método para a sua preparaçao
DE69534878D1 (de) Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren
NO993847L (no) FremgangsmÕter og preparater for behandling av allergisk astma og andre sykdommer ved anvendelse av deskarboetoksyloratadin
MY113490A (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
NO954612L (no) Metoder og preparater for å behandle ooforektomiserte kvinner
WO1992018160A3 (en) Method for inhibiting adhesion of white blood cells to endothelial cells
CA2278616A1 (en) Adenoviruses having altered hexon proteins
DK0865294T3 (da) Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
Linardaki, KA Boki, A Fertakis, AG Tzioufas Pure Red Cell Aplasia as Presentation of Systemic Lupus Erythematosus: Antibodies to Erythropoietin: CASE REPORT
Bartholomew et al. Investigation of relationships between collagens, elastin and proteoglycans in bovine thoracic aorta by immunofluorescence techniques
EP0482089A4 (en) Methods of treating or preventing autoimmune uveoretinitis in mammals
Tsutsui et al. Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation
GEP20002257B (en) Method for Reducing Fibrin Accumulation Speed, Prophylactics of Thrombus Complications and Treatment of Blood Vessels Diseases, Medicinal Composition and Medicinal Species
AU6299596A (en) Prevention of a disease having the characteristics of diabetes
Meier-Ruge et al. Effect of yttrium 90 on experimental allergic arthritis in rabbits.
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
WO1989000166A3 (en) Growth hormone related peptide
SE9300139D0 (sv) Manufacture of a new drug
EP0791360A3 (en) Treatment of septic shock with anti-TNF antibodies
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees